Loading...
•
Mar 31, 2022
Cerus Q1 2022 Earnings Report
Total revenue grew 46% year-over-year, driven by INTERCEPT platelet uptake in the U.S., and full-year product revenue guidance was increased.
Key Takeaways
Cerus Corporation reported a strong first quarter with a 46% increase in total revenue, driven by increased sales of INTERCEPT platelet kits in the U.S. The company increased its full-year product revenue guidance from $157-164 million to $160-165 million.
Total revenue increased by 46% year-over-year to $43.0 million.
Product revenue increased by 60% year-over-year to $37.4 million, driven by INTERCEPT platelet kits in the U.S.
Net loss improved by $5.2 million to $12.3 million, or $0.07 per share.
Full-year 2022 product revenue guidance was increased to $160-165 million, representing approximately 22%-26% growth.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company expects full-year 2022 product revenue will be in the range of $160-165 million, representing strong growth of approximately 22%-26% compared to full-year 2021 product revenue of $130.9 million.
Positive Outlook
- Strong growth of approximately 22%-26% compared to full-year 2021
- Increased demand for INTERCEPT platelet kits
- Continued progress scaling up operations
- Additional manufacturing capacity coming online in 2022
- Financial discipline, resulting in operating leverage
Challenges Ahead
- Risks associated with commercialization and market acceptance of the INTERCEPT Blood System
- Risks associated with the ultimate duration and severity of the COVID-19 pandemic
- Risks related to Fresenius Kabi’s efforts to assure an uninterrupted supply of platelet additive solution (PAS)
- Risks related to adverse market and economic conditions
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...